About Contact Us Careers
Sign In

Nuclear Medicine Market Size & Share, by Product (Diagnostic Products, Therapeutic Products); Application (Cardiology, Neurology, Oncology); End-user (Hospitals & Clinics, Diagnostic Centers) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 4456
  • Published Date: Feb 13, 2023
  • Report Format: PDF, PPT

Companies Dominating the Nuclear Medicine Landscape

top-features-companies
    • GE Healthcare
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Jubilant Pharmova Limited
    • Nordion (Canada), Inc.
    • Bracco Imaging S.P.A
    • The Institute for Radioelements (IRE)
    • NTP Radioisotopes SOC Ltd.
    • The Australian Nuclear Science and Technology Organization (ANSTO)
    • Mallinckrodt Pharmaceuticals
    • Lantheus
    • Eckert & Ziegler
Browse Key Market Insights with Data Illustration:

In the News

  • A new generation nuclear medicine scanner for use in cardiac imaging has been unveiled by GE Healthcare. It has an expanded field-of-view processing capability and new automated workflow features for a quick, comfortable exam. MyoSPECT provides a remarkable picture of cardiac architecture and pathology to aid doctors in choosing the best course of treatment for patients. It was developed using the company's proprietary Alcyone technology and CZT module design.

  • The Institute for Radioelements (IRE), a pioneer in the manufacturing of Molybdenum-99 (Mo-99), the radioisotope that is most frequently used in nuclear medicine for diagnostics, announced that it has produced its first batch of Mo-99 Low Enriched Uranium (LEU) for the US market.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4456
  • Published Date: Feb 13, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are growing prevalence of cardiovascular diseases, growing geriatric population, new product launches by key players, and others.

The market is anticipated to attain a CAGR of 20% over the forecast period, i.e., 2023-2033.

Availability of alternatives, limited number of trained medical professional, and supply shortage are some of the major factors expected to hinder the growth of the market.

The market in Asia Pacific is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are GE Healthcare, Jubilant Pharmova Limited, Nordion (Canada), Inc., Bracco Imaging S.P.A, and more.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product, application, end-user, and by region.

The oncology segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying